發(fā)布時間：2018-04-22 14:18

  本文選題：藥品 + 醫(yī)保藥品支付標(biāo)準(zhǔn)　； 參考：《中國衛(wèi)生政策研究》2017年11期

【摘要】：建立針對藥品的醫(yī)療保險支付標(biāo)準(zhǔn)(參考價)是多國控制藥品費用不合理增長的重要措施。醫(yī)保藥品支付標(biāo)準(zhǔn)通過藥品價格競爭刺激患者需求和增強患者選擇的權(quán)利來影響醫(yī)生行為和藥品企業(yè)定價。我國放開藥品政府定價后也亟需建立適應(yīng)藥品市場發(fā)展的價格形成機制,建立醫(yī)保藥品支付標(biāo)準(zhǔn)需要從我國藥品管理政策轉(zhuǎn)變和現(xiàn)狀出發(fā),厘清控費的具體機制,根據(jù)當(dāng)前我國實踐中存在的問題,從藥物經(jīng)濟學(xué)評價、藥品分級分類管理、完善醫(yī)保藥品支付方式和補償機制、合理分配補償結(jié)余等方面入手,提升藥品的可及性、費用的可控性和政策的激勵性。
[Abstract]:Establishing the standard of medical insurance payment for drugs (reference price) is an important measure to control the unreasonable increase of drug cost in many countries. The standard of health care drug payment affects the behavior of doctors and the pricing of drug companies by stimulating patients' demand and enhancing patients' right to choose by means of drug price competition. After our country liberalizes the drug government pricing, it is urgent to establish the price forming mechanism that adapts to the development of the drug market. To establish the medical insurance drug payment standard, we need to clarify the specific mechanism of the control fee from the transformation and the present situation of the drug management policy in our country. According to the problems existing in the practice of our country at present, starting with the aspects of the evaluation of pharmacoeconomics, the classification and management of drugs, the improvement of the payment mode and compensation mechanism of medical insurance drugs, the rational distribution of compensation balance, and so on, the availability of drugs can be improved. Cost control and policy incentives.
【作者單位】： 湖北經(jīng)濟學(xué)院財政與公共管理學(xué)院;
【基金】：湖北省教育廳人文社會科學(xué)研究項目(17Q142)
【分類號】：R95

【相似文獻】

相關(guān)碩士學(xué)位論文 前1條

1 劉桂圓;藥品價格改革形勢下醫(yī)保藥品支付標(biāo)準(zhǔn)的研究[D];東南大學(xué);2017年

，

本文編號：1787598